Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus KEFLEX.
CEFOXITIN IN PLASTIC CONTAINER vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, and PBP2, thereby inhibiting transpeptidation and leading to cell lysis. It is a cephamycin antibiotic resistant to beta-lactamase hydrolysis due to a 7-alpha-methoxy group.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV every 6-8 hours; maximum 12 g/day
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.5 hours (approximately 45-90 minutes); prolonged to 2-6 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe renal impairment (CrCl <10 mL/min).
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion; biliary: <2%; fecal: trace.
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic